Open Access Research

Development of the ATAQ-IPF: a tool to assess quality of life in IPF

Jeffrey J Swigris1*, Sandra R Wilson2, Kathy E Green3, David B Sprunger1, Kevin K Brown1 and Frederick S Wamboldt4

Author Affiliations

1 Autoimmune Lung Center and Interstitial Lung Disease Program, National Jewish Health, 1400 Jackson Street, Denver, Colorado, 80206, USA

2 Palo Alto Medical Foundation Research Institute, Palo Alto Medical Foundation, 795 El Camino Real, Palo Alto, California, 94301, USA

3 Morgridge College of Education, University of Denver, 2199 S University Blvd, Denver, Colorado, 80210, USA

4 Division of Psychosocial Medicine, National Jewish Health, 1400 Jackson Street, Denver, Colorado, 80206, USA

For all author emails, please log on.

Health and Quality of Life Outcomes 2010, 8:77  doi:10.1186/1477-7525-8-77

Published: 31 July 2010

Abstract

Background

There is no disease-specific instrument to assess health-related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF).

Methods

Patients' perspectives were collected to develop domains and items for an IPF-specific HRQL instrument. We used item variance and Rasch analysis to construct the ATAQ-IPF (A Tool to Assess Quality of life in IPF).

Results

The ATAQ-IPF version 1 is composed of 74 items comprising 13 domains. All items fit the Rasch model. Domains and the total instrument possess acceptable psychometric characteristics for a multidimensional questionnaire. The pattern of correlations between ATAQ-IPF scores and physiologic variables known to be important in IPF, along with significant differences in ATAQ-IPF scores between subjects using versus those not using supplemental oxygen, support its validity.

Conclusions

Patient-centered and careful statistical methodologies were used to construct the ATAQ-IPF version 1, an IPF-specific HRQL instrument. Simple summation scoring is used to derive individual domain scores as well as a total score. Results support the validity of the ATAQ-IPF, and future studies will build on that validity.